Used as a prodrug form of meropenem, this compound enhances the stability and oral bioavailability of the active antibiotic. It is designed to resist degradation in the gastrointestinal tract, allowing for effective delivery of meropenem upon enzymatic or chemical cleavage in the body. This approach supports the development of oral formulations for carbapenem antibiotics, which are typically administered intravenously. It holds potential in extending the use of broad-spectrum beta-lactam antibiotics to outpatient settings, improving patient compliance and reducing healthcare costs.